Skip to main content
Premium Trial:

Request an Annual Quote

Sphere Fluidics Closes $2M Financing Round

NEW YORK (GenomeWeb) — Sphere Fluidics announced today that it has closed a $2 million investment round.

Investors in the round included Greenwood Way Capital, Oxford Technology and Innovations, EIS Fund, and 24Haymarket.  

Cambridge, England-based Sphere said it will use the funding to expand its operations and support sales of its Cyto-Mine single-cell analysis system.

Launched in 2017, the system automates single-cell screening, sorting, imaging, and dispensing to speed biopharmaceutical discovery. Earlier this month, Sphere signed an agreement to integrate Peak Analysis and Automation's automated microplate handling technology into the system.

"We are making further investment in automating and streamlining our manufacturing processes across our product range to extend our offering and to deliver our high-quality standards and service to more researchers working in biotherapeutic discovery and cell line development across the UK and USA," Sphere CEO Frank Craig said in a statement. "We will be raising additional funds to expand these capabilities further."